GI Oncology Now Roundtable
Focus on Upper GI
Personalized Care in Gastric and Esophageal Cancers: Biomarkers, Diagnosis, and Treatment Approaches
The panel focuses on the management of gastroesophageal cancers, highlighting differences in presentations across regions.
The panel explores advancements in early-stage esophageal cancer, emphasizing the paradigm shift toward FLOT chemotherapy.
The panel covers updates on 1L treatments for metastatic gastric cancer, including the recent approval of tislelizumab.
The panel considers tislelizumab amid existing PD-1 inhibitors, zolbetuximab for Claudin-positive patients, and more.
The panel covers ASPEN-O6 results, excitement around ADCs in late-line HER-2 and Claudin-positive cancers, and more.
Advertisement
Focus on Gastric Cancer
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
Advertisement
Focus on Colorectal Cancer
The panel focuses on the evolution of CRC treatment paradigms, including advances in chemo, biologic agents, and more.
The panel swaps opinions on advancements in EGFR and KRAS inhibitors, as well as the importance of NGS and liquid biopsy.
The panel details strategies for managing oligometastatic CRC, emphasizing the importance of a multidisciplinary approach.
The panel expands on the incorporation of ctDNA in the CRC adjuvant setting, highlighting its prognostic value.
The panel explores sequencing challenges for therapies like fruquintinib, TAS-102, and sotorasib for colorectal cancer.
The panel concludes with the challenges of implementing cutting-edge research into colorectal cancer care and practice.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.